$RGNX

Six Montgomery County companies raised over $566 million in Q3. Forbright (Nasdaq) completed an IPO, raising $142.2 million. Xometry (Nasdaq) announced a $225 million secondary offering. RegenxBio (Nasdaq) raised $90.04 million in a public offering. Georgiamune secured $92.69 million in venture funding. Arculus Solutions raised $1.95 million in Seed-1 funding. Jesse & Ben raised $15 million in Series A funding.

REGENXBIO (RGNX) presented at Morgan Stanley's conference, highlighting progress in its gene therapy pipeline. RGX-202 showed higher microdystrophin expression than Elevidys, with reduced liver injury. RGX-314 Phase III data is expected in Q4 2024. The company has a cash runway through Q4 2027, with potential AbbVie milestones extending it to 2028. RGX-121 remains on clinical hold due to MRI findings. Shares have declined 44.83% year-to-date, trading at $7.95.

Regenxbio Inc. (RGNX) faced an FDA clinical hold for RGX-121, its gene therapy for Hunter syndrome, due to spinal abnormalities in five patients. Shares fell over 24% premarket. The abnormalities were deemed non-serious and likely benign, with patients asymptomatic. The FDA's full clinical-hold letter and additional data are awaited to determine next steps.

On August 28, 2026, notable insider trading included Optimum Communications (OPTU) director Neil S. Subin buying $2.45M in shares, REGENXBIO (RGNX) director Gregory Austin Ciongoli purchasing $949K, and Pulse Biosciences (PLSE) COO Liane Rae Teplitsky acquiring $99K. United States Antimony (UAMY) CEO Gary C. Evans bought $98K in shares, while Battalion Oil (BATL) director William D. Rogers purchased $91K. On the sell side, Life Time Group (LTH) insiders sold $126M, Relay Therapeutics (RLAY) 10%

REGENXBIO (RGNX) faces an FDA clinical hold on its Hunter Syndrome gene therapy (RGX-121) due to asymptomatic spinal MRI findings in five participants. The company is evaluating additional data with partner NS Pharma. Other late-stage programs, including RGX-202 for Duchenne muscular dystrophy and surabgene lomparvovec for wet AMD, remain on track. The Hunter Syndrome treatment market is projected to grow to $1.8B by 2030, according to Grandview Research.

President Trump may fire FDA Commissioner Marty Makary, according to the Wall Street Journal. Several biotech and pharmaceutical companies, including Replimune (REPL), uniQure (QURE), Moderna (MRNA), and others, have publicly clashed with the FDA over drug-review processes. Shares of REPL, QURE, and MRNA rose 17%, 15%, and 10% respectively at the time of writing.

On August 28, 2026, 183 insider stock purchases were reported. Notable transactions include Klarna Group's CEO buying 692,506 shares for $9.95M, Medifast's Kiai Parsa purchasing 41,975 shares for $514,747, and Regenxbio's Ciongoli buying 53,407 shares for $499,675. Hawkins' Lange and FTC Solar's Sadasivam also made significant purchases.

Regenxbio Inc (RGNX) shares rose 7.1% premarket after director Gregory Ciongoli bought 102,603 shares at $9.14-$9.36 each, totaling over $950,000. Ciongoli also received restricted stock units and stock options. His total ownership increased to 118,035 shares.

Ciongoli Gregory Austin purchased 102,603 shares of REGENXBIO Inc. (RGNX) at an average of $9.25 ($9.14–$9.36, $0.95M total) across 2 trades over 2026-08-26 to 2026-08-27.

REGENXBIO Inc. (RGNX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EXHIBIT 99.1 REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli ROCKVILLE, Md., August 25, 2026 – REGENXBIO Inc. (Nasdaq: RGNX) today announced the appointment of Greg Ciongoli to its Board of Directors, effective August 25, 2026. With multiple upcoming ca